Facing the CDK4/6i resistance dilemma in patients with breast cancer, exploration of the resistance mechanism and possible reverse strategy: A narrative review. Issue 51 (23rd December 2022)

• Record Type: Journal Article
• Authors: Wu, Jiayi; Wang, Wei; Shao, Xiying; Lin, Guang; Wang, Xiaojia
• Is Part Of: Medicine. Volume 101:Issue 51(2022)
• Page Start: e32238
• Publication Date: 2022-12-23
• Subjects: biomarker, reverse treatment strategies -- breast cancer -- CDK4/6i -- resistance mechanism; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000032238
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Breast cancer is one of the highest rates of malignancy of women, approximate 70% metastatic breast cancer are hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2−). Hormone therapy is the primary strategy of HR+/HER2− metastatic breast cancer. With the permission of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i), progress free survival and overall survival were significantly licensed. However, inevitable outcome of CDK4/6i resistance has become the main reason that restricts the clinical benefit of patients. In recent years, the research on dealing with drug resistance has become a hot topic, a large number of molecular mechanisms have been focused, and a lot of experiments have been carried out at the preclinical level. This review summarizes the current knowledge of CDK4/6i resistance mechanism, systematically expounds the signaling pathways and targets leading to CDK4/6i resistance, analyzes different ways and mechanisms, and provides theoretical guidance for the clinical reversal of endocrine therapy resistance.